GenPhar’s AV-Finder™-HIV is an extremely efficient and flexible high-throughput screening (HTS) assay for anti-HIV drug discovery that offers the potential for significant savings. This in vitro drug-screening tool, based on our patented indicator cell system, allows us to assist researchers interested in the efficient identification and validation of new antiviral agents against HIV-1.
- Offers an initial phase to determine if a compound has any anti-HIV activity, compared to an internal control generating substantial savings in contrast to commercially available screens.
- Phase II consists of a more definitive and quantitative determination of a compound’s IC50, IC90, EC50, and Selectivity Index (S.I.) values.
- Phase III provides measurement of a compound’s performance against established drug resistant strains.
- Can accommodate any early stage or late stage anti-HIV inhibitors.
- Provides information about the mechanism of antiviral activity.
- Provides valuable data about drug solubility, cell uptake, and cytotoxicity.
- Can be utilized to find new anti-HIV inhibitors that are not cross-resistant with other approved antiretroviral drugs currently on the market.
- Can identify all types of HIV-1 inhibitors, regardless of the underlying mechanism of action involved.
- Has been tested with a number of different clades of HIV-1.
GenPhar’s AV-Finder™-HIV Technology
Since GenPhar’s AV-Finder™-HIV is a cell-based assay, information regarding the cytotoxicity of the test compounds for human cell cultures and selectivity for inhibition of virus replication will be determined. Solubility and uptake of the test compounds by the cells (bioavailability) will also be determined and, in the 2nd and 3rd phases of the assay, the IC50, IC90, EC50, and Selectivity Index (S.I.) values for the candidate drugs exhibiting anti-HIV activity characteristics in the initial screen can be readily determined.
***GenPhar offers volume discounts for Phase I HTS services